key: cord-0052309-tm9ig7ge
authors: nan
title: Acknowledgement to Referees
date: 2020-11-05
journal: Clin Pharmacokinet
DOI: 10.1007/s40262-020-00958-z
sha: d5fe78fc8814420b0a199f73dacae7f4a281eb68
doc_id: 52309
cord_uid: tm9ig7ge

nan

The high quality of the content published in Clinical Pharmacokinetics has been reflected in the most recent Impact Fac-tor™ of 4.604 (placing the journal in the top quartile of the 'Pharmacology & Pharmacy' category) and CiteScore™ of 8.8 (placing the journal in the top quartile of the 'Pharmacology [Medical]' category). Further, Clinical Pharmacokinetics has published content in a timely manner, with an average time from submission to first decision of 33 days.

In 2021, Clinical Pharmacokinetics will continue to provide you with high interest, clinically relevant content in the field of clinical pharmacokinetics and pharmacodynamics. We thank you for your continued support.

With best wishes, Amitabh Prakash and Anton van Rensburg

The COVID-19 pandemic has reinforced the importance of rapid and wide dissemination of high-quality information

Springer Nature is supporting the global response to COVID-19 by making all relevant content immediately and freely available. Indeed

Comparative population pharmacokinetics of darunavir in SARS-CoV-2 patients vs. HIV patients: the role of interleukin-6

Pharmacokinetics/pharmacodynamics of antiviral agents used to treat SARS-CoV-2 and their potential interaction with drugs and other supportive measures: a comprehensive review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents

Chloroquine for SARS-CoV-2: Implications of its unique pharmacokinetic and safety properties